NAV

Butacaine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Butacaine
DrugBank Accession Number
DB11502
Background

Not Available

Type
Small Molecule
Groups
Approved, Vet approved
Structure
3D
Similar Structures
Weight
Average: 306.45
Monoisotopic: 306.230728214
Chemical Formula
C18H30N2O2
Synonyms
  • Butacaina
  • Butacaine
  • Butacainum

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AbemaciclibThe risk or severity of methemoglobinemia can be increased when Abemaciclib is combined with Butacaine.
AbirateroneThe risk or severity of methemoglobinemia can be increased when Abiraterone is combined with Butacaine.
AcetaminophenThe risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Butacaine.
AcetazolamideThe risk or severity of methemoglobinemia can be increased when Acetazolamide is combined with Butacaine.
Acetic acidThe risk or severity of methemoglobinemia can be increased when Acetic acid is combined with Butacaine.
Acetyl sulfisoxazoleThe risk or severity of methemoglobinemia can be increased when Acetyl sulfisoxazole is combined with Butacaine.
AdagrasibThe risk or severity of methemoglobinemia can be increased when Adagrasib is combined with Butacaine.
AfatinibThe risk or severity of methemoglobinemia can be increased when Afatinib is combined with Butacaine.
AldesleukinThe risk or severity of methemoglobinemia can be increased when Aldesleukin is combined with Butacaine.
AlectinibThe risk or severity of methemoglobinemia can be increased when Alectinib is combined with Butacaine.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Butacaine sulfatePAU39W3CVB149-15-5VWZAGCZUPZKTET-UHFFFAOYSA-N
International/Other Brands
Butyn
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Welders Eye EaseButacaine sulfate (.14 %) + Boric acid (2.31 %) + Camphor (2 %) + Thimerosal (4.07 %) + Witch hazel (6.39 %)LiquidOphthalmicCanadian Custom Packaging Company1965-12-312006-03-21Canada flag

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as benzoic acid esters. These are ester derivatives of benzoic acid.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Benzoic acid esters
Alternative Parents
Aminobenzoic acids and derivatives / Benzoyl derivatives / Aniline and substituted anilines / Trialkylamines / Carboxylic acid esters / Amino acids and derivatives / Monocarboxylic acids and derivatives / Primary amines / Organopnictogen compounds / Organooxygen compounds
show 2 more
Substituents
Amine / Amino acid or derivatives / Aminobenzoic acid or derivatives / Aniline or substituted anilines / Aromatic homomonocyclic compound / Benzoate ester / Benzoyl / Carboxylic acid derivative / Carboxylic acid ester / Hydrocarbon derivative
show 10 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
Z84S23CGJJ
CAS number
149-16-6
InChI Key
HQFWVSGBVLEQGA-UHFFFAOYSA-N
InChI
InChI=1S/C18H30N2O2/c1-3-5-12-20(13-6-4-2)14-7-15-22-18(21)16-8-10-17(19)11-9-16/h8-11H,3-7,12-15,19H2,1-2H3
IUPAC Name
3-(dibutylamino)propyl 4-aminobenzoate
SMILES
CCCCN(CCCC)CCCOC(=O)C1=CC=C(N)C=C1

References

General References
  1. Guyer P, Fritze D: [Dimorphism of butacaine sulfate]. Arzneimittelforschung. 1974 Dec;24(12):1978-9. [Article]
  2. Jung DW, Brierley GP: Energy-dependent contraction of swollen heart mitochondria--activation by butacaine. Arch Biochem Biophys. 1979 Mar;193(1):76-87. [Article]
  3. Henderson EG, Volle RL: Asymmetrical blockade of potassium exchange in muscle by SKF 525-A: comparison with butacaine. J Pharmacol Exp Ther. 1974 Mar;188(3):553-63. [Article]
  4. O'MALLEY WE, FORREST JW, KRANTZ JC Jr: A note on the detection of atropine sulfate in the presence of butacaine sulfate. J Am Pharm Assoc Am Pharm Assoc. 1954 Dec;43(12):769. [Article]
  5. Fayle DR, Barritt GJ, Bygrave FL: The effect of butacaine on adenine nucleotide binding and translocation in rat liver mitochondria. Biochem J. 1975 Jun;148(3):527-31. [Article]
  6. LOOMIS TA, JESSEPH JE, BEYER RE: Prolongation of the anticoagulant action of heparin with procaine and butacaine conjugates. J Pharmacol Exp Ther. 1952 Jan;104(1):87-92. [Article]
  7. LOOMIS TA, JESSEPH JE: A clinical study of prolonged anticoagulant effect with repository butacaine heparin. J Pharmacol Exp Ther. 1952 Sep;106(1):83-7. [Article]
  8. Dorris RL, Gage TW: The effects of butacaine hemisulfate on brain and heart catecholamine concentrations of the mouse. Pharmacol Res Commun. 1980 Feb;12(2):155-61. [Article]
  9. Muller WH, Freimuller B: [Effect of procaine, nicotinoylprocaine and butacaine on mammalian cells in culture]. Arzneimittelforschung. 1984;34(10):1250-3. [Article]
  10. Crompton M, Barritt GJ, Bradbury JH, Bygrave FL: The interaction between butacaine and rat liver mitochondria as shown by proton magnetic resonance spectroscopy. Biochem Pharmacol. 1976 Nov 15;25(22):2461-4. [Article]
ChemSpider
2386
BindingDB
50225491
RxNav
1829
ChEBI
94820
ChEMBL
CHEMBL129529
ZINC
ZINC000001596184
Wikipedia
Butacaine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
LiquidOphthalmic
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0424 mg/mLALOGPS
logP4.46ALOGPS
logP3.87Chemaxon
logS-3.9ALOGPS
pKa (Strongest Basic)10.55Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area55.56 Å2Chemaxon
Rotatable Bond Count12Chemaxon
Refractivity93.42 m3·mol-1Chemaxon
Polarizability37.85 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00di-4901100000-9352f9280ad39739ab8d

Drug created at February 26, 2016 17:25 / Updated at March 03, 2021 21:57